Nebivololo E Idroclorotiazide Mylan (Hydrochlorothiazide, Nebivolol)

Nebivolol/Hydrochlorothiazide, the active ingredients in Nebivololo E Idroclorotiazide Mylan, are a beta‑blocker/thiazide diuretic combination presented as a tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Nebivololo E Idroclorotiazide Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol/Hydrochlorothiazide is used to manage hypertension, a condition characterized by elevated arterial pressure.

- Essential hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk. - Secondary hypertension: assists in controlling blood pressure when the underlying cause is identified. - Isolated systolic hypertension: helps achieve target systolic pressures in older adults.

Common Side Effects: - Dizziness or light‑headedness. - Headache. - Fatigue or mild weakness. - Increased urination. - Electrolyte disturbances such as low potassium.

Serious or Rare Side Effects: - Severe hypotension. - Significant electrolyte imbalances (e.g., hyponatremia, hypokalemia). - Acute kidney injury. - Bradycardia. - Allergic reactions including rash or angioedema.

Patients should be monitored for blood‑pressure response and renal function, and electrolyte levels should be checked regularly.

- Blood‑pressure monitoring: ensure adequate control without excessive lowering. - Renal function assessment: adjust use in impaired kidney function. - Electrolyte surveillance: watch for hypokalemia or hyponatremia. - Diabetes caution: monitor blood glucose as diuretics may affect glucose control. - Discontinuation: avoid abrupt cessation to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol/Hydrochlorothiazide may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other antihypertensives (e.g., ACE inhibitors, ARBs) may cause additive hypotension. - Potassium‑sparing diuretics: risk of hyper‑kalemia. - Lithium: increased lithium levels and toxicity. - Strong CYP2D6 inhibitors (e.g., paroxetine): raise nebivolol concentrations.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce diuretic efficacy and affect renal function. - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment. - Calcium‑channel blockers: may enhance blood‑pressure lowering effect.